Investigators at Mayo Clinic Discuss Findings in Multiple Myeloma (Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma: Post Hoc 18-month Follow-up of a Phase 1 Trial)

Press/Media

Period27 Oct 2023

Media coverage

1

Media coverage

  • TitleInvestigators at Mayo Clinic Discuss Findings in Multiple Myeloma (Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma: Post Hoc 18-month Follow-up of a Phase 1 Trial)
    Media name/outletNewsRx Hematology Daily
    Country/TerritoryUnited States
    Date27/10/23
    PersonsSundar Jagannath
View all 1
View less

Related content